Prostate Cancer Clinical Trials in Detroit

Showing 141-160 of 355 trials

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

NCT03787680

The purpose of this study is to test the effectiveness (how well the drugs work), safety, and tolerability of the investigational drug combination of olaparib and AZD6738 for all patients with metastatic castration-resistant prostate cancer.

Prostate Cancer

University of Michigan Rogel Cancer Center49 participantsStarted Oct 2019

Ann Arbor, Michigan, United States • Detroit, Michigan, United States • Charlottesville, Virginia, United States

COMPLETEDPhase 2< 1 mile

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

NCT01309672

RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body. It may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well abiraterone acetate works in treating patients with prostate cancer who have undergone initial hormone therapy.

Prostate Cancer

SWOG Cancer Research Network41 participantsStarted Aug 2011

Jonesboro, Arkansas, United States • Little Rock, Arkansas, United States • Rogers, Arkansas, United States +202 more locations

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Prostate Cancer Trials in Other Cities

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Comprehensive Outcomes for After Cancer Health

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)

Other Conditions in Detroit